Zai Lab Limited

Hello ladies and gentlemen, thank you for standing by and welcome to Xilabs second quarter 2026 financial results conference call. At this time all participants are in listen only mode. Later we'll conduct a question and answer session and instructions will follow at a time. As a reminder, today's call is being recorded. It is now my pleasure to turn the floor over to Christine Chiou Senior Vice President of the Investor Relations. Please go ahead, ma'am.

Thank you, operator. Hello and welcome, everyone. Today's earnings call will be led by Dr. Samantha Du, Scilabs founder, CEO, and chairperson. She will be joined by Dr. Rafael Amado, President and Head of Global Research and Development, and Dr. Yajing Chen, Chief Financial Officer. Dr. Shan He, our Chief Business Officer, and Dr. Yuzhe Wang, Our operating partner will also be available to answer questions during the Q&A portion of the call. As a reminder, during today's call, we will be making certain forward-looking statements based on our current expectations. These statements are subject to numerous risks and uncertainties that may cause actual results to differ materially from what we expect due to a variety of factors, including those discussed in our SDC filings. We will also refer to adjusted loss from operations, which is a non-GAAP financial measure. please refer to our earnings release furnished with the SEC on August 6th, 2026 for additional information on this non-GAAP financial measure. At this time, it is my pleasure to turn the call over to Dr. Samantha Du.

Thanks, Christine. Good morning and good evening, everyone. Thank you for joining us today. That lab has reached the important inflection point in its evolution from original business into a global biopharmaceutical company. We built this company by bringing first-of-best-in-class medicine to patients in China. Today, we are developing our own innovative medicine for patients worldwide with our first U.S. regulatory submission expected next year. The transformation reflects the R&D capabilities we have built We're conducting global multiple center registritional oncology trials, advancing additional clinical programs across oncology and immunology, and advancing our clinical pipeline into INDs this year. So see, our potential first and best-in-class DL3 ADC demonstrates what XyLab is capable of. We advance it. from IMD to Global Pivotal Trials in less than two years, reflecting the speed and efficiency of the integrated development organization we have built. By the end of this year, we expect to have three registrational programs in small cell lung cancer and neuroendocrine carcinoma. We're also evaluating ZOSI in combination with T-cell engagers through collaborations with Amjin and Borenger-Ying Gehan. Our second major global opportunity is GL1503, a potential first-in-class long-acting IL-31 bispecific for atopic dermatitis. We believe it has the potential to bring together multiple attributes in a single asset, robust skin clearance, Rapid and durable yeast reduction and longer dosing interval. Later this year, we'll report the program's first human data. At the same time, we continue to strengthen our commercial business. This quarter, we sharpened our focus behind our highest priority brands. Night product revenue grew 11% versus previous quarter. and the business remain commercially profitable. We're setting a strong foundation and expect a return to meaningful year-on-year growth in 2027, followed by the potential for our first U.S. product launch in 2028. SciLife's evolution into a global biopharmaceutical company is well underway. with a growing portfolio of globally developed differentiated medicines and a profitable commercial business. We're confident in the path ahead and the long-term value we can create for shareholders and patients. With that, let me turn the call over to Rafael to further discuss our pipeline in greater detail. Thank you.